An observational study in Erectile Dysfunction, Coronary Artery Disease and Ejaculation Disorders, sponsored by Saglik Bilimleri Universitesi. Completed at 2 sites in Turkey (Türkiye). Open to male participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Saglik Bilimleri Universitesi · Observational
This observational, cross-sectional study aims to compare erectile and ejaculatory function between men with a history of coronary revascularization and men without known coronary artery disease.
The study included 135 adult male participants, including 66 men who had previously undergone percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and 69 men without known coronary artery disease.
Erectile function was evaluated using the Sexual Health Inventory for Men (SHIM), premature ejaculation symptoms using the Premature Ejaculation Diagnostic Tool (PEDT), and ejaculatory function using the Male Sexual Health Questionnaire-Ejaculatory Dysfunction (MSHQ-EjD). Self-reported ejaculation latency was also assessed.
The primary objective was to investigate the association between previous coronary revascularization and erectile function. Secondary objectives included comparing premature ejaculation symptoms, ejaculatory function, and ejaculation latency between the two groups.
This observational, cross-sectional, comparative study was conducted among adult male patients attending cardiology and urology outpatient clinics. The study investigated whether a history of coronary revascularization was associated with differences in erectile and ejaculatory function.
A total of 135 male participants were included. Participants were divided into two groups according to their cardiovascular history. The coronary revascularization group consisted of 66 men who had previously undergone percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). The comparison group consisted of 69 men without a known history of coronary artery disease or coronary revascularization.
Participants in the revascularization group were evaluated at least one month after their most recent PCI or CABG procedure. Patients receiving dialysis, those with cirrhosis, those with a left ventricular ejection fraction below 40%, and those who had undergone coronary revascularization within the preceding month were excluded.
Erectile function was assessed using the five-item Sexual Health Inventory for Men (SHIM), with lower scores indicating poorer erectile function. Premature ejaculation symptoms were assessed using the Premature Ejaculation Diagnostic Tool (PEDT). Ejaculatory function and ejaculation-related distress were evaluated using the Male Sexual Health Questionnaire-Ejaculatory Dysfunction (MSHQ-EjD). Self-reported ejaculation latency was recorded in minutes.
The primary outcome was the SHIM score. Secondary outcomes included PEDT scores, MSHQ-EjD scores, and self-reported ejaculation latency.
Between-group comparisons were performed using the Mann-Whitney U test and Fisher's exact test, as appropriate. Multivariable linear regression was performed to evaluate the association between coronary revascularization history and SHIM scores after adjustment for age, diabetes mellitus, hypertension, and smoking status. Body mass index was additionally included in a sensitivity analysis.
No experimental treatment or study-specific therapeutic intervention was administered. All assessments were performed as part of a single observational evaluation.
698 studies on the registry are indexed under Erectile Dysfunction; 116 are open to participants now.
This study's enrollment of 135 is close to the median of 135 across 120 observational studies indexed under Erectile Dysfunction.
Browse Erectile Dysfunction studies →Saglik Bilimleri Universitesi is the lead sponsor of 447 studies on the registry; 138 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consisted of 135 adult male participants recruited from cardiology and urology outpatient clinics. Participants were categorized into two groups according to their cardiovascular history: 66 men with previous coronary revascularization (PCI or CABG) and 69 men without known coronary artery disease or coronary revascularization. Sexual function was evaluated using standardized self-administered questionnaires, including the SHIM, PEDT, and MSHQ-EjD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adult male participants without a known history of coronary artery disease, percutaneous coronary intervention, or coronary artery bypass grafting (n = 69). Sexual function was assessed using the SHIM, PEDT, and MSHQ-EjD questionnaires
Adult male participants with a history of coronary artery disease who had undergone percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) at least one month before questionnaire assessment (n = 66). Sexual function was assessed using the SHIM, PEDT, and MSHQ-EjD questionnaires.
Erectile Function Assessed by SHIM
Erectile function was assessed using the five-item Sexual Health Inventory for Men (SHIM). Total scores range from 5 to 25, with lower scores indicating poorer erectile function. A score of 21 or lower was considered positive for erectile dysfunction screening.
Time frame: At enrollment (single assessment)
Premature Ejaculation Symptoms
Premature ejaculation symptoms were assessed using the five-item Premature Ejaculation Diagnostic Tool (PEDT). Total scores range from 0 to 20, with higher scores indicating a greater likelihood of premature ejaculation. Scores of 11 or higher were considered positive screening results.
Time frame: At enrollment (single assessment)
Ejaculatory Function
Ejaculatory function was evaluated using the sum of the first three items of the Male Sexual Health Questionnaire-Ejaculatory Dysfunction (MSHQ-EjD). Higher scores indicate better ejaculatory function.
Time frame: At enrollment (single assessment)
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jul 2026 to primary completion in Oct 2026, 3 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saglik Bilimleri Universitesi →